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Purpose: Gastric cancer (GC) is still a relevant health issue worldwide. The identification of
prognostic factors for progression of gastric dysplasia (GD), the main pre-cancerous lesion of
the intestinal-type GC, is hence mandatory.
Patients and methods: A cohort of 83 GD endoscopic samples belonging to Italian
subjects was collected. hERG1 expression was evaluated by immunohistochemistry and
scored 0–3, depending on the percentage of stained cells. Expression data were analysed in
conjunction with clinico-pathological and survival data.
Results: hERG1 turned out to be expressed in 67.47% (56 out of 83) of the GD samples.
hERG1 expression was higher in high-grade GD compared to low-grade GD (29 out of 39,
74.36% vs 27 out of 44, 61.36%), although the statistical significance was not reached
(P=0.246). No association emerged between hERG1 expression and clinical features of the
patients (age, gender, localization, H. pylori infection, gastritis and intestinal metaplasia). In
a subset of cases for which sequential samples of gastric lesions (from GD to Early Gastric
Cancer and Advanced Gastric Cancer) were available, hERG1 expression was maintained in
all the steps of gastric carcinogenesis from GD onwards. A general trend to increased
expression in advanced lesions was observed. hERG1 score had a statistically significant
impact on both Progression-Free Survival (P=0.018) and Overall Survival (P=0.031). In
particular, patients displaying a high hERG1 score have a shorter survival.
Conclusion: hERG1 is aberrantly expressed in human GD samples and has an impact on
both PFS and OS, hence representing a novel prognostic marker for progression of GD
towards GC of the intestinal histotype. Once properly validated, hERG1 detection could be
included in the clinical practice, during endoscopic surveillance protocols, for the manage-
ment of GD at higher risk of progression, as already proposed for Barrett’s oesophagus.
Keywords: Kv11.1, immunohistochemistry, endoscopic surveillance in gastric dysplasia,
prognosis, intestinal type gastric adenocarcinoma
Introduction
Gastric cancer (GC) is still a leading cause of death nowadays, and according to the
Globocan estimates in 2018, more than 1 million people were diagnosed with GC,
with nearly 800,000 deaths associated to such disease (source: Globocan 2018,
https://gco.iarc.fr/). In Europe, it has been estimated that in 2018, roughly 143,000
people developed GC, with a high mortality rate (100,000 people) (source:
Globocan 2018, https://gco.iarc.fr/). Several risk factors for GC have been identified
over years and pre-neoplastic lesions have been described. In 2012, the European Society
of Gastrointestinal Endoscopy issued guidelines to be followed for the management of
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gastric precancerous lesions. According to these guidelines,
surveillance and treatment are recommended for subjects with
chronic gastritis, atrophy, intestinal metaplasia and dysplasia;
for these conditions, a screening of the general population is
not necessary.1 Gastric dysplasia (GD) is defined as a pre-
neoplastic lesion for intestinal-type GC and it is associated to a
higher risk, especially in case of high-grade lesions. GD arises
due to abnormalities accumulated by the cells of the gastric
lining mucosa. GD might be classified into two types: low-
grade (LGD) and high-grade dysplasia (HGD) according to
the level of disorganization, nuclear and architectural atypia.2,3
In LGD, cells grow slowly, lesions can regress and the risk of
cancer progression is low; on the other hand, in HGD, the
abnormal cells have several atypical features, grow quickly
and the risk of progressing to GC is high: 0–23% for LGD and
60–85% for HGD.1 Due to the intra- and inter-observer differ-
ences, the assessment of the grade of GD might be highly
subjective, and although recently the molecular profile of
gastric pre-neoplastic lesions has been partially elucidated,
no markers useful to discriminate between hyperplasia and
LGD or between HGD and early tumours are currently
available.4
Moreover, the management and treatment of the two
types of GD are different due to their diverse associated
risk to progress to GC; therefore, the identification of
progression markers is strongly needed.
Among novel potential biomarkers, ion channels and
transporters have been described to be altered in several
tumours and regulate different cellular processes (reviewed
in Ref. 5).
hERG1 (also named Kv11.1 or KCNH2), a potassium
channel encoded by KCNH2 gene, is not expressed by normal
non-excitable tissues as well as hyperplastic lesions of colon
and endometrium.6,7On the other hand, hERG1 is expressed in
pre-neoplastic lesions of the oesophagus (Barrett’s oesopha-
gus, BO),8 and more recently, we showed that its expression
increases during progression from BO to adenocarcinoma.9
More strikingly, a statistically significant association between
hERG1 and risk of progression to adenocarcinomawas found.9
The aim of the present paper was to evaluate hERG1
expression in gastric dysplasia and to search for associa-
tion with clinico-pathological features and follow-up.
Materials And Methods
Tissue Collection
Eighty-three gastric dysplasia samples were retrieved from
the archives of different Italian institutions (Department of
Experimental and Clinical Medicine, University of Florence,
Florence, Italy; Pathology Division, Esine Hospital, ASST
della Valcamonica, Italy; Pathology Division, Azienda
Ospedaliero-Universitaria Senese, Siena, Italy; Pathology
Division, Borgo Trento Hospital, Verona, Italy; Pathology
Division, Morgagni-Pierantoni Hospital, Forlì, Italy). The
study was approved by the local ethical committee following
current guidelines about retrospective observational studies
in biological samples, and for each patient, a written
informed consent was obtained.
Diagnosis and histological grading were assessed using
standard criteria by experienced pathologists in each insti-
tution (LM, MC, CV, AT and LS).
For 76 patients, detailed follow-up information were
available. Moreover, for 7 patients whose lesions pro-
gressed towards malignancy, slides of the gastric adeno-
carcinoma were also evaluated.
Immunohistochemistry (IHC)
IHC was performed as previously reported6 using an anti-
hERG1Monoclonal antibody (MCK Therapeutics, Florence,
Italy). Briefly, sections were dewaxed, dehydrated and incu-
bated with 1% H2O2 solution in PBS to block endogenous
peroxidases’ activity. Antigen retrieval was performed with
Proteinase K (5 μg/mL) for 5 mins at 37°C and sections were
then treated with a blocking solution (Ultra V Block,
LabVision; Fremont CA, USA). Samples were incubated
overnight at 4°C and the following day immunostaining
was carried out with a commercially available kit (PicTure
Max kit, Invitrogen; Carlsbad CA, USA).
Scoring Assessment
hERG1 expression was estimated as the percentage of posi-
tive cells. Samples were classified into four groups according
to the percentage of positive cells: 0% (addressed as “0”),
1–25% (addressed as “Score 1”), 26–49% (addressed as
“Score 2”) and >50% (addressed as “Score 3”) as previously
reported.10 Slides were analysed field by field from top left to
bottom right, under 40x magnification by two independent
investigators (EL and MRR).
Statistical Methods
Data were analysed using the statistical softwares Stata 9.1
(StataCorp, College Station, TX, USA) and SAS 9.4 (SAS
Institute Inc, Cary, NC, USA). Presence of association
between hERG1 expression and demographic, clinical and
biological characteristics was evaluated by Fisher’s exact test
Lastraioli et al Dovepress
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or Chi-square test, as appropriate. In any case, a two-sided
P value ≤ 0.05 was considered significant.
hERG1 expression was investigated for its impact on
Progression-Free Survival (PFS) and Overall Survival
(OS). PFS was defined as the time between diagnosis and
progression of the disease or last follow-up, OS was defined
as the time between diagnosis and death, whatever the cause.
Observation time of patients alive at the last follow-up was
censored. PFS and OS were estimated by Kaplan–Meier
method and hazard ratios (with the corresponding 95% CI)
were calculated by Cox regression model.
Results
hERG1 Channel Is Expressed In Gastric
Dysplasia Samples
hERG1 potassium channels were found to be expressed in
GD samples with variable intensity of staining and
percentage of positive cells (Figure 1). In the representa-
tive pictures reported in Figure 1, some samples showed a
quite intense staining (Figure 1B) while in other samples
(Figure 1A), the protein was present at lower intensity.
Overall, hERG1 channels turned out to be expressed in
a high percentage of GD samples (67.47%, 56 out of 83)
(Figure 1C). When subdividing the samples according to
hERG1 score (described in Materials and Methods), a
variable distribution was observed (Figure 1D).
When GD samples were analysed according to the
grade of dysplasia, it emerged that hERG1 was expressed
in a higher percentage of HGD with respect to LGD
(29 out of 39, 74.36% vs 27 out of 44, 61.36%), although
no statistically significant difference emerged neither con-
sidering positive vs negative samples or subdividing the
samples according to hERG1 scoring (P=0.246 and
P=0.650, respectively) (Figure 2).
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Figure 1 hERG1 expression in representative examples of gastric dysplasia samples. (A) Score 1 sample. (B) Score 3 sample. Bar: 100 μm. (C) Graph bar summarizing
hERG1 expression in GD samples. White bar: negative samples; Blue bar: positive samples. (D) Distribution of hERG1 scoring in GD samples. White bar: negative samples;
Light blue bar: Score 1 samples. Azure bar: Score 2 samples. Blue bar: Score 3 samples.
Dovepress Lastraioli et al
OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com
DovePress
9379
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
93
.4
7.
22
9.
17
5 
on
 1
9-
De
c-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Association With Clinico-Pathological
Features
A statistical analysis was performed to search for eventual
association between hERG1 expression, demographic para-
meters and clinico-pathological features.
No association emerged when analysing age, gender,
localization and grade of dysplasia according to hERG1
expression.
In a subset of patients for whom additional data were
available, we also evaluated eventual associations
between hERG1 expression and H. pylori infection, gas-
tritis, intestinal metaplasia: no statistically significant
association emerged from such analysis. The same
analyses were also performed considering hERG1 scoring
and similar results were obtained (not shown).
All the data obtained through statistical analysis are
summarised in Table 1.
Association With Progression And
Survival
We analysed 7 patients for which sequential lesions were
available. In the pictures shown in Figure 3A, slides
belonging to a representative patient are reported.
hERG1 expression was absent in gastric healthy
mucosa, with the exception of oxyntic mucosa (see
inset), confirming what already published by our group;10
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Figure 2 hERG1 expression in LGD and HGD samples. (A) LGD sample. (B) HGD sample. Bar: 100 μm. (C) Distribution of hERG1 scoring in LGD and HGD samples.
White bars: negative samples; Blue bars: positive samples.
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in metaplasia, a certain degree of hERG1 positivity was
observed, confirming what already published in Barrett’s
oesophagus.8,9 The expression of the channel is main-
tained throughout all the steps of gastric carcinogenesis
from LGD and HGD to Early Gastric Cancer (EGC) and
Advanced Gastric Cancer (AGC). In Figure 3B, a graph
bar summarizing the results of the evaluation of hERG1
scoring in 7 patients for whom samples of the sequential
lesions were available. As it can be observed, in 3/7
patients hERG1 scoring was higher in cancers than in
GD, for one patient the scoring was equal in both lesions
and for 3/7 patients hERG1 scoring was higher in GD than
in cancer.
The median follow-up of the patients was 24 months
and it emerged that hERG1 scoring had an impact on both
PFS and OS. In particular, when analysing PFS, it emerged
that patients with higher hERG1 expression have a shorter
PFS both considering hERG1 scoring (Figure 4A) and
Table 1 hERG1 Scoring Association With General Parameters And Clinico-Pathological Features
Score 0 Score 1 Score 2 Score 3 P-Value
Gender (n=83) Female 12 (34.29) 7 (20.00) 7 (20.00) 9 (25.71) 0.507
Male 13 (31.71) 13 (31.71) 4 (9.76) 11 (26.83)
Localisation (n=52) Antrum 15 (42.86) 6 (17.14) 5 (14.29) 9 (25.71) 0.674
Body 4 (30.77) 4 (30.77) 3 (23.08) 2 (15.38)
Gastric Stump 1 (25.00) 2 (50.00) 0 (0.00) 1 (25.00)
H. pylori infection (n=37) Yes 7 (41.18) 5 (29.41) 2 (11.76) 3 (17.65) 0.900
No 7 (35.00) 5 (25.00) 2 (10.00) 6 (30.00)
Gastritis
(n=40)
Yes 13 (37.14) 11 (31.43) 4 (11.43) 7 (20.00) 0.416
No 1 (20.00) 1 (20.00) 0 (0.00) 3 (60.00)
Grade of Dysplasia (n=83) Low Grade 17 (38.64) 10 (22.73) 6 (13.64) 11 (25.00) 0.650
High Grade 10 (25.64) 10 (25.64) 8 (20.51) 11 (28.21)
Intestinal Metaplasia (n=39) Yes 12 (44.44) 6 (22.22) 3 (11.11) 6 (22.22) 0.281
No 1 (12.50) 4 (50.00) 1 (12.50) 6 (22.22)
Notes: Statistical analysis was performed with Fisher Exact Test or Chi-square test as appropriate, as described in Materials and Methods.
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Figure 3 hERG1 expression in gastric carcinogenesis. A) Slides belonging to a representative patient. Bar: 100 μm. B) hERG1 scoring in seven patients for whom slides of
sequential lesions were available. Blue bars: GD samples; Orange bars: GC samples.
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hERG1 positive vs negative samples (Figure 4B) (P=0.018
and P=0.003, respectively). When analysing OS, statisti-
cally significant association emerged both considering
hERG1 scoring (P=0.031) (Figure 4C) and subdividing
the samples in only two classes using as a cut-off 25%
of positive cells (P=0.006) (Figure 4D). In particular,
patients displaying a high hERG1 scoring (≥25%, corre-
sponding to Score 2 and 3) have shorter survival in terms
PFS
OS
A
C
B
D
Figure 4 Kaplan–Meier plots of PFS and OS according to hERG1 scoring. Score 0: blue curve; Score 1: red curve; Score 2: green curve; Score 3: brown curve. (A) PFS
within the four classes. (B) PFS in low (Score 0 and 1; <25%) and high (Score 2 and 3; ≥25%) hERG1 expression. (C) OS of the patients subdivided in four classes according
to hERG1 scoring; (D) OS of patients with low and high hERG1 expression, defined as above.
Table 2 Results Of The Univariate PFS And OS Analyses.
hERG1
Scoring
PFS OS
HR (95% CI) P-Value HR (95% CI) P-Value
0 1.00 0.034a 1.00 0.254
1 0.64 (0.13–3.19) –
2 3.76 (1.26–11.22) 10.35 (1.07–100.29)
3 2.56 (0.90–7.24) 6.05 (0.67–54.96)
0–1 1.00 0.005a 1.00 0.026a
2–3 3.39 (1.44–7.99) 10.92 (1.32–90.12)
Note: aIndicates statistical significance.
Table 3 Results Of Chi-Square Test, Evaluating Follow-Up
According To hERG1 Scoring
hERG1
Scoring
Follow-Up, n (%)
Regression Stable
Disease
Progression
0 15 (41.67) 4 (21.05) 6 (33.33)
1 14 (38.89) 2 (10.53) 3 (16.67)
2 2 (5.56) 6 (31.58) 3 (16.67)
3 5 (13.89) 7 (36.84) 6 (33.33)
Lastraioli et al Dovepress
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of both PFS and OS (Figure 4) and are therefore at higher
risk (Table 2).
These results are in accordance with that obtained
analysing progression (identified by the clinicians during
follow up visits) according to hERG1 scoring (P=0.017,
Table 3), although in this case, no statistically significant
results were obtained when considering just two categories
(Negative vs Positive samples, P=0.327).
Discussion
Gastric dysplasia represents the main pre-neoplastic lesion
of the human stomach, and the estimation of risk to pro-
gression for this group of patients is still a great challenge.
In this manuscript, we provide evidence that hERG1
channels are overexpressed in human GD samples and are
associated to an increased risk. It is well known that
hERG1 is expressed both in GC cell lines11,12 and primary
tumours.10,13,14
Mounting evidence has been gathered concerning
hERG1 channels (and potassium channels in general)
expression and role in solid tumours comprising GC
(reviewed in Refs.15 and 16), but little has been reported
in preneoplastic lesions.
We showed long ago that hERG1 channels are
expressed in Barrett’s oesophagus,8 and more recently,
we demonstrated that they represent novel biomarkers of
oesophageal tumour progression.9 A similar scenario
seems to apply to GC progression, and in the present
paper, we provided evidence that i) hERG1 are expressed
in GD samples; ii) hERG1 channels are expressed in a
higher percentage of HGD with respect to LGD; iii)
hERG1 channels are associated to the disease progression;
iv) hERG1 expression is maintained during all the phases
of the cancerogenetic process starting from intestinal
metaplasia; and v) high hERG1 expression is associated
to poorer progression-free and overall survival.
This last point is in accordance with our observation
obtained in other tumours such as oesophageal
adenocarcinoma,9 pancreatic ductal adenocarcinomas,17
and clear cell renal carcinomas.18 As in oesophageal ade-
nocarcinomas, the identification of at-risk patients is a
quite challenging issue, but it is mandatory since GC
prognosis is still very poor.
Conclusion
Overall, the detection of hERG1 expression in gastric
dysplastic lesions could represent a novel prognostic
marker of progression towards gastric adenocarcinoma of
the intestinal histotype.
Moreover, hERG1 detection could be also exploited for
diagnostic purposes in clinical practice for high-risk GD
management, such as endoscopic surveillance protocols, as
proposed for oesophageal tumours.9 Nevertheless, it is
important to stress out that these results represent a pilot
study and confirmation on bigger cohorts of patients is
warranted.
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